

Chondrosarcoma CS Foundation



Virtual Dialogues

Chondrosarcoma Foundation, Inc. Fifth International Virtual Dialogue
 Wednesday, October 4, 2023
 7:00PM – 9:00PM (EST / NY) via Zoom

Future Initiatives for the Diagnosis and Treatment of Chondrosarcoma
 The Chondrosarcoma Foundation, Inc. will host their fifth International Forum / Virtual Dialogue featuring the following prominent experts to address new innovations, findings, and technologies to improve the treatment of Chondrosarcoma.

Please register at: <https://csfshayna.org/virtual-dialogue5-registration>

How Research & Clinical Trials will Advance New Methods to Treat Chondrosarcoma
 William D. Tap, MD, is a medical oncologist, and the Chief of Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York City. Dr. Tap explains that it is difficult to develop broad treatment approaches for Chondrosarcomas. However, the paradigm is shifting as nuances within these rare diseases are being better understood. As such, unique treatment opportunities are being developed internationally for patients with Chondrosarcoma and other soft tissue sarcomas. According to Dr. Tap, "broad program project areas are researching drug development and translational medicine to inform how to optimally tailor therapy to individual patients."

The Role of Interventions & Medications to Treat Chondrosarcoma
 Jonathan C. Trent, M.D., is the Associate Director Clinical Research, and the Director of Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center in Miami, FL. His work involves the use of novel preoperative and postoperative clinical trials, prospectively acquired tumor tissue, cell lines, and relationships with disciplines such as the genomics, surgical oncology, pathology, and radiology. Dr. Trent will provide an overview of medical interventions and medications including Ivosidenib / (Tibsovo), an IDH1 biomarker inhibitor used in treating Chondrosarcoma.

Neuropeptide PRP-1 and its analogs potential in the treatment of Chondrosarcoma by targeting cancer stem cells
 Karina Galoian, Ph.D., is a research associate professor in the Dept of Orthopaedics at the University of Miami Leonard M. Miller School of Medicine and is Research Director of the Sarcoma Disease Site Group at Sylvester Comprehensive Cancer Center. Dr. Galoian is a Principal Investigator of Musculoskeletal Oncology Signal Transduction Laboratory. Her research is focused on neuropeptide derivatives to target specific populations of cancer stem cells and destroy them in chondrosarcomas and soft tissue sarcomas. These cells are responsible for drug and therapy resistance, cancer spread and recurrence.

CSPG4 as a Target for CAR-T Cell Therapy to Treat High Grade Chondrosarcoma
 Joseph H. Schwab, M.D., MS, is the professor of orthopedic surgery and neurosurgery and the Director of the Center for Surgical, Artificial Intelligence for Cedars Sinai Hospital in Los Angeles, CA. Dr. Schwab combines his spine surgery and oncology training with his research interests in tumors and degenerative conditions of the spine. Dr. Schwab will address the research he conducts using Car-T therapy to treat high grade Chondrosarcoma.

Critical Pathways & Target Treatment Approaches to Treat Chondrosarcoma
 Andrew J. Wagner, MD, PhD, is the Associate Chief Medical Officer at Dana-Farber Cancer Institute and the Medical Director of Adult Ambulatory Oncology. He is a medical oncologist and researcher in the Center for Sarcoma and Bone Oncology and Assistant Professor of Medicine at Harvard Medical School. Dr. Wagner focuses on the treatment of patients with sarcoma and conducts research and clinical studies to identify new targets and treatments. He has led Phase I through Phase III studies of targeted agents in sarcomas and other solid tumors.

Join us for this very informative forum. Please register at:
<https://csfshayna.org/virtual-dialogue5-registration>

David Bowles

CS Awareness Day Patient Tributes

David Bowles lost his battle to Chondrosarcoma on August 19, 2022. He was a CS Warrior, a champion and supporter to the community. He would always share both his experiences with proton radiation and Tibsovo and how that treatment extended his life without surgery. He offered his advice and support to anyone suffering from this rare bone cancer.

David's goal was to help people facing this disease and advocated moving treatment options away from surgery. David joined the board of the Chondrosarcoma Foundation in 2020. David's contributions to the CS community and to the CS Foundation will always be remembered.



CHONDROSARCOMA AWARENESS DAY

SHAYNA ELISE KRAMER



FEBRUARY 6th, 2024



The Chondrosarcoma CS Foundation, Inc. proclaims February 6th, 2024 as Chondrosarcoma Awareness Day to honor the legacy of **Shayna Elise Kramer** who passed away from this rare cancer in 2019.

CS Awareness Events

THE CHONDROSARCOMA FOUNDATION HOSTS

STEPPIN' FOR A CAUSE

SATURDAY OCTOBER 21ST 2023
 START AT 10:00 AM
 LOCATION: ALLEN POND PARK, BOWIE MD

Letting Data Tell Your Story Chondrosarcoma Patient Registry

The Chondrosarcoma Patient Registry is a powerful, useful tool for individuals with chondrosarcoma and their family members to contribute directly to research that will enhance our understanding of this rare bone cancer.

For more information about how to register, [click here](#).

Information Publications for CS Patients

Chondrosarcoma: What You Need to Know

Selecting a Sarcoma Treatment Center:
 How to Find a Chondrosarcoma Oncologist / Treatment Center



www.csfshayna.org



info@csfshayna.org



Chondrosarcoma CS Foundation Support